Skip to main content
SpringerLink
Log in
Book cover

Betablocker im neuen Jahrtausend pp 60–66Cite as

Plötzlicher Tod: ACE-Hemmer und β-Blocker

  • Chapter

  • 35 Accesses

Zusammenfassung

Der plötzliche Tod ist ein extrem häufiges Ereignis bei Patienten, die an kardiovaskulären Erkrankungen leiden. Von den Patienten, die in klinischen Studien versterben, stirbt mindestens ein Drittel von denen mit Hypertonie, wahrscheinlich ungefähr die Hälfte derer, die einen Myokardinfarkt überlebt haben, und die Hälfte derer mit Herzinsuffizienz plötzlich, β-Blocker reduzieren das Risiko des plötzlichen Todes bei Patienten mit kardiovaskulären Erkrankungen, insbesondere bei Postinfarktpatienten oder Patienten mit Herzinsuffizienz. ACE-Hemmer sind vielleicht weniger effektiv. Für andere kardiovaskuläre Medikamente ist eine Reduktion des Risikos des plötzlichen Todes bisher nicht nachgewiesen.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   34.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   44.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators (1993) Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342: 821–828

    Google Scholar 

  2. Beta Blocker Heart Attack Research Group (1982) A randomized trial of propranolol in patients with acute myocardial infarction. 1. Mortality results. JAMA 247: 1707–1713

    Article  Google Scholar 

  3. CIBIS-II Investigators and Committees (1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) a randomised trial. Lancet 353: 9–13

    Article  Google Scholar 

  4. Cleland JGF, Alamgir F (1999) Aspirin, myocardial infarction, and gastrointestinal bleeding. Lancet 353: 676

    Article  PubMed  CAS  Google Scholar 

  5. Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekbom T, Wester PO (1991) Morbidity and mortality in the Swedish Trial in old patients with hypertension (STOP-Hypertension). Lancet 338: 1281–1285

    Article  PubMed  Google Scholar 

  6. Freemantle N, Cleland J, Young P, Mason J, Harrison J (1999) β-blockade after myocardial infarction: systematic review and meta regression analysis. Br Med J 318: 1730–1737

    Article  CAS  Google Scholar 

  7. Hansson L, Zanchetti A, Carruthers G, Dahlöf B, Elmfeldt D, Ménard J, Julius S, Rahn K, Wedel H, Westerling S, HOT Study Group (1998) Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351: 1755–1762

    Article  PubMed  CAS  Google Scholar 

  8. Held PH, Yusuf S (1993) Effects of beta-blockers and calcium channel blockers in acute myocardial infarction. Eur Heart J 14: 18–25

    Article  PubMed  Google Scholar 

  9. Hennekens CH, Albert CM, Godfried SL, Gaziano MJ, Buring JE (1996) Adjunctive drug therapy of acute myocardial infarction — evidence from clinical trials. NEJM 335: 1660–1667

    Article  PubMed  CAS  Google Scholar 

  10. Køber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Trandolapril Cardiac Evaluation (TRACE) Study group et al. (1995) A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. NEJM 333: 1670–1676

    Article  PubMed  Google Scholar 

  11. Kuller LH (1980) Sudden death: definition and epidemiologic considerations. Prog Cardiovasc Dis 23: 1–12

    Article  PubMed  CAS  Google Scholar 

  12. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and broad range of initial cholesterol levels. NEJM 339: 1349–1357

    Article  Google Scholar 

  13. Medical Research Council Working Party (1985) MRC trial of treatment of mild hypertension: principal results. Br Med J 291: 97–104

    Article  Google Scholar 

  14. MERIT-HF Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 353: 2001–2007

    Article  Google Scholar 

  15. The Norwegian Multicenter Study Group (1981) Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. NEJM 304: 801–807

    Article  Google Scholar 

  16. Nuttall SL, Toescu V, Kendall MJ (2000) β-blockade after myocardial infarction. Br Med J 320: 581

    Article  CAS  Google Scholar 

  17. Olsson G, Wikstrand J, Warnold I, Manger Cats V, McBoyle D, Herlits J, Hjalmarson A, Sonnenblick EH (1992) Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials. Eur Heart J 13: 28–32

    PubMed  CAS  Google Scholar 

  18. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, Davis BR et al. (1992) Effect of Captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. NEJM 327: 669–677

    Article  PubMed  CAS  Google Scholar 

  19. Sacks F, Pfeffer M, Moye L et al. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. NEJM 335: 1001–1009

    Article  PubMed  CAS  Google Scholar 

  20. Scandinavian Simvastatin Survival Study Group (1994) Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383–1389

    Google Scholar 

  21. Schatzkin A, Cupples A, Heeren T, Morelock S, Kannel WB (1984) Sudden death in the Framingham Heart Study. Differences in incidence and risk factors by sex and coronary disease status. Am J Epidemiol 120 (6): 888–899

    PubMed  CAS  Google Scholar 

  22. SHEP Cooperative Research Group (1991) Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 265: 3255–3264

    Article  Google Scholar 

  23. Siscovick DS, Raghunathan TE, Psaty BM (1994) Diuretic therapy for hypertension and the risk of primary cardiac arrest. NEJM 330: 1852–1857

    Article  PubMed  CAS  Google Scholar 

  24. Soumerai S, McLaughlin T, Spiegelman D, Hertzmarck E, Thibault G, Goldman L (1997) Adverse outcomes of underuse of β-blockers in elderly survivors of acute myocardial infarction. JAMA 277: 115–121

    Article  PubMed  CAS  Google Scholar 

  25. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze G, Birkenhäger WH, Bulpitt C, Leeuw P, Dollery CT, Fletcher A, Forette F, Leonetti G, Nachev C, O’Brien E, Rosenfeld J, Rodicio JL, Tuomilehto J (1997) Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 350: 757–764

    Article  PubMed  CAS  Google Scholar 

  26. Wikstrand J, Warnold I, Olsson G, Toumilehto J, Elmfeldt D, Berglund G (1988) Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA 259: 1976–1982

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Pharmacology Section, Department of Medicine, Queen Elizabeth Hospital, Edgbaston, Birmingham, B15 2TH, UK

    Dr. M. J. Landray MRCP

Authors
  1. Dr. M. J. Landray MRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Universitätsklinikum Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany

    P. Dominiak

  2. Abteilung für Pathophysiologie, Zentrum für Innere Medizin, Universitätsklinikum Essen, Hufelandstraße 55, 45122, Essen, Germany

    G. Heusch

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Steinkopff Verlag Darmstadt

About this chapter

Cite this chapter

Landray, M.J. (2001). Plötzlicher Tod: ACE-Hemmer und β-Blocker. In: Dominiak, P., Heusch, G. (eds) Betablocker im neuen Jahrtausend. Steinkopff. https://doi.org/10.1007/978-3-642-93720-0_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-93720-0_6

  • Publisher Name: Steinkopff

  • Print ISBN: 978-3-642-93721-7

  • Online ISBN: 978-3-642-93720-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation